Ajanta Pharma Limited CC-Dec23.pdf · 2024-01-31
Sir, my question is in terms of strategy, you talked about the impact in the cardiovascular segment. Given that we have cash in hand and we have also been in the industry for such a long time that we can expand the footprint, etc. So, can you talk a little bit more about what we can do to improve the growth specifically in the cardiovascular space, which has been a little lower than what we had expected?
Sir, with cash in hand, and I think a lot of companies are buying brands and making acquisitions. Do you think as a strategy you would be looking to acquire certain brands, work on brands or certain divisions to accentuate your already strong presence in the domestic market?